Oncology News

Using fecal hemoglobin concentrations to guide colorectal cancer screening intervals reduced the number of fecal immunochemical tests and colonoscopies by 49% and 28%, respectively, compared with biennial screening, data showed.

Treatment for Helicobacter pylori infection was associated with reduced risk for gastric cancer among patients with a high genetic risk, suggesting that chemoprevention should be personalized to genetic risk, according to data.

The FDA granted accelerated approval adagrasib with cetuximab for the treatment of KRASG12C -mutated locally advanced or metastatic colorectal cancer, according to a press release from the agency.

National Accreditation Program for Rectal Cancer accreditation appeared associated with better outcomes for older adults who underwent major rectal cancer surgery, according to findings in Journal of the American College of Surgeons.

In a new clinical practice guideline, the AGA provides evidence-based recommendations for use of endoscopic eradication therapy in the management of Barrett’s esophagus, accounting for the presence of dysplasia and other scenarios.

CHICAGO — A phase 2 study evaluating dostarlimab in adults with mismatch repair-deficient locally advanced rectal cancer has maintained a 100% clinical complete response rate at a median follow-up of almost 18 months.

CHICAGO — The microbiome profile of early-onset pancreatic adenocarcinoma is distinct from that of average-onset disease, according to findings presented at ASCO Annual Meeting.

CHIGAGO — Perioperative chemotherapy improved OS in patients with locally advanced esophageal adenocarcinoma compared with chemoradiation prior to surgery, results form a randomized phase 3 trial presented at ASCO Annual Meeting showed.

CHICAGO — Combination immunotherapy significantly improved outcomes vs. first-line chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, according to study results.

CHICAGO — Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC-01 study presented at ASCO Annual Meeting.